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Platelet Inhibition
IIb/IIIa Inhibition in ACS: Which Patient and Which Drug?
Three articles in this issue address the question of which patients with acutecoronary syndromes (ACS) benefit from glycoprotein IIb/IIIa inhibition and
which of the available drugs is themost effective. The small EVEREST trial, presented
by Bolognese and colleagues, compared three different IIb/IIIa regimens in patients
with high-risk ACS (chest pain at rest, electrocardiographic changes, elevated tropo-
nin). Patients treated with upstream tirofiban were 3 to 5 times more likely to have a
Thrombolysis In Myocardial Infarction frame count of 2 or 3 at the end of the
procedure than were patients treated with either an in-cath lab high-bolus dose of
tirofiban or in-cath lab abciximab. In the second article, Glaser and colleagues com-
piled previously published trial results to develop a cost-effectiveness model for the use
of IIb/IIIa inhibitors in patients with ACS. In the most likely scenarios, the use of
upstream tirofiban or eptifibatide has an acceptable cost-effectiveness ratio for the
slightly improved mortality rates in comparison with the provisional use of abciximab
at the time of percutaneous coronary intervention. An editorial by Dr. Ben-Yehuda
discusses the pathophysiology involved duringACS and the rationale and relevant data
for the various regimens. See pages 522, 529, and 538. See figure.
Chronic Coronary
Artery Disease
BNP Predicts Future Cardiac Events in Patients With Stable Angina
B-type natrurietic peptide (BNP) has been shown to provide prognostic informa-tion in patients with congestive heart failure and acute myocardial infarction.
There is evidence to suggest that smaller amounts of BNP may be released by
chronically ischemic cardiac myocytes that are not necrosing. Schnabel and colleagues
studied baseline BNP levels in over 1,000 patients with known coronary artery disease
and stable symptoms and followed them for future cardiac events. The average BNP in
patients with a future cardiovascular event was 119 pg/ml versus 36 pg/ml in those
without an event. A value over 100 indicated a 4.4-fold increased risk of future events
and provided evidence of increased risk regardless of left ventricular systolic function.
This study expands the cohorts of patients inwhomelevatedBNPpredicts an increased
risk of future cardiac events. See page 552.
The Synthetic Steroid Tibolone Reverses Myocardial Perfusion Defects
Tibolone is a synthetic steroid that is widely used in Europe to treat symptoms ofmenopause and/or osteoporosis; it has not yet been approved in the U.S. It
appears tohavedifferent stimulatory or inhibitory effects ondifferent tissue types; some
previous work has suggested that it may have beneficial effects on endothelial function
and actually promote fibrinolysis in contrast to estrogen. In this small, open-label trial,
postmenopausal women with inducible perfusion defects on single-photon emission
computed tomographic scans were randomized to either tibolone or usual care, with
repeat scanning six months later. Campisi and colleagues report that there was an
improved summeddifference score in 9 of 10 subjects treatedwith tibolone versus only
1 of 11 treated with usual care. This study suggests a dramatic improvement in
ischemic burden can be achieved with this specific activity steroid and the need for
larger trials with cardiovascular and other end points. See page 559.
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Coronary Risk Factors
and Endothelial Dysfunction
Impaired Myocardial Blood Flow in Subjects at Risk for Cardiac Events
Traditional cardiovascular risk factors predict future cardiovascular outcomes but itis unknown if they correlate with absolute myocardial blood flow (MBF) mea-
sured in milliliters of blood per gram of tissue per minute. Wang and colleagues
measured MBF at rest and after adenosine-induced vasodilation in subjects with
cardiovascular risk factors butno symptomsusing cardiacmagnetic resonance imaging.
They report that both resting and hyperemicMBFwere lower inmen than in women,
even after considering age andmenopausal status.Theperfusion reserve (PR—the ratio
of hyperemic to resting MBF) was independently associated with hypertension and
higher low-density lipoprotein cholesterol levels. Hyperemic MBF and PR correlated
strongly and inverselywith estimated10-year cardiac risk basedonFraminghamscores,
suggesting that this method can detect subclinical atherosclerosis and is another
method to predict future cardiac events. See page 565. See figure.
Page 586
Heart Failure
Decreased Plasma Clearance of BNP in Chronic Renal Insufficiency
Although it has been recognized that patients with chronic renal insufficiency tendto have higher levels of B-type natriuretic peptide (BNP), it has been
unclear if this reflected worse hemodynamics or reduced plasma clearance of the
peptide. Tsutamoto and colleagues studied nearly 400 people with varying degrees
of heart and kidney failure. By simultaneously measuring the amount of BNP in
the aorta and the coronary sinus, they were able to determine the amount excreted
by the heart. They report consistent and fairly robust correlations between left
ventricular ejection fraction, left ventricular end-diastolic pressure (LVEDP), and
BNP in the coronary sinus; the correlations with BNP level in the aorta were less
robust and more dependent on the glomerular filtration rate (GFR). With similar
LVEDP, plasma BNP is about twice as high when the GFR is60 ml/min versus
60 ml/min. See page 582. See figure.
Page 591
Heart Rhythm Disorders
Tilt Table Testing Unreliable for Diagnosing Vasovagal Syncope
The validity of head-up tilt table testing (HUT) for diagnosing the etiology ofvasovagal syncope (VVS) is controversial. Some have advocated that if HUT
provokes a bradycardic response, a pacemaker may be beneficial in preventing further
episodes, but the clinical trial evidence supporting this strategy is conflicting.This study
by Deharo and colleagues used implantable loop recorders in 25 patients with highly
symptomatic VVS and a positiveHUT and compared the response duringHUTwith
what was observed during unprovoked episodes of VVS. They found no correlation
betweenHUT and the actual rhythm observed during VVS. They also report that the
initial rhythm observed during spontaneous syncope was consistent for patients with
multiple episodes of syncope. This study suggests that properly diagnosing the etiology
of syncope may lead to more effective treatment strategies but that HUT is not useful
in diagnosing the etiology of VVS. See page 587. See figure.
(continued) A-42Diabetes and Obesity
Increased Myocardial Fatty Acid Metabolism in Diabetics
Inaddition tohaving advanced rates of atherosclerosis, diabetes is also associatedwithhigher rates of non-ischemic cardiomyopathies and larger infarctions when similar
areas of myocardium appear to be in jeopardy. Animal models have shown that while
in non-diabetic subjects the cellular energy source for oxidative metabolism switches
between fatty acids, glucose, and lactate, in diabetics it is mostly confined to oxidation
of fatty acids. Herrero and colleagues used a variety of radioisotope-labeled tracers to
compare oxidativemetabolism in subjects with type 1 diabetes and controls. Confirm-
ing the animal models, myocardial glucose utilization was 50% less in subjects with
diabetes, whereas myocardial fatty acid oxidation was 400% higher. This study con-
firms the validity of animalmodels of themyocardial effects of diabetes and sheds light
on someof the pathologybehind thehigher rates of cardiovascular problems in subjects
with diabetes. See page 598.
